Stem cell-based therapeutic strategies for corneal epithelium regeneration

Nosrati, Hamed; Alizadeh, Zohreh; Nosrati, Ali; Ashrafi-Dehkordi, Korosh; Banitalebi-Dehkordi, Mehdi; Sanami, Samira; Khodaei, Mohammad

doi:10.1016/j.tice.2020.101470

Cited by 24 publications

(20 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to now, oral mucosa epithelial cells and MSCs are the only non-limbal epithelial cells that have been proven to be safe and effective for treating patients with ocular surface failure due LSCD [ 55 , 89 ]. Nevertheless, during the last few years, other alternative sources of non-limbal cells have also been investigated in experimental studies with different degrees of success [ 34 , 170 , 171 , 172 ] ( Figure 6 ).…”

Section: The Future: Challenges To Overcome In Stem Cell-based Therapiesmentioning

confidence: 99%

Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency

et al. 2021

View full text Add to dashboard Cite

Corneal failure is a highly prevalent cause of blindness. One special cause of corneal failure occurs due to malfunction or destruction of the limbal stem cell niche, upon which the superficial cornea depends for homeostatic maintenance and wound healing. Failure of the limbal niche is referred to as limbal stem cell deficiency. As the corneal epithelial stem cell niche is easily accessible, limbal stem cell-based therapy and regenerative medicine applied to the ocular surface are among the most highly advanced forms of this novel approach to disease therapy. However, the challenges are still great, including the development of cell-based products and understanding how they work in the patient’s eye. Advances are being made at the molecular, cellular, and tissue levels to alter disease processes and to reduce or eliminate blindness. Efforts must be coordinated from the most basic research to the most clinically oriented projects so that cell-based therapies can become an integrated part of the therapeutic armamentarium to fight corneal blindness. We undoubtedly are progressing along the right path because cell-based therapy for eye diseases is one of the most successful examples of global regenerative medicine.

show abstract

Section: The Future: Challenges To Overcome In Stem Cell-based Therapiesmentioning

confidence: 99%

Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Here, we will specifically emphasize the development of cornea mimics that use cells in combination with natural biomaterials that explore patient outcomes in animal models or serve as in vitro tissue models. Many cell types have been investigated for use in corneal tissue engineering, including corneal endothelial cells (CEnCs), corneal epithelial cells (CEpCs), corneal epithelial stem cells (CEpSCs), keratocytes (CKs), mesenchymal stem cells (MSCs), adipose-tissue derived stem cells (ASCs), and embryonic-derived stem cells [ 132 , 133 , 134 ].…”

Section: Engineering a Cornea Mimetic: Cell Types And Their Functionmentioning

confidence: 99%

Recent Advances in Natural Materials for Corneal Tissue Engineering

et al. 2021

View full text Add to dashboard Cite

Given the incidence of corneal dysfunctions and diseases worldwide and the limited availability of healthy, human donors, investigators are working to generate engineered cellular and acellular therapeutic approaches as alternatives to corneal transplants from human cadavers. These engineered strategies aim to address existing complications with human corneal transplants, including graft rejection, infection, and complications resulting from surgical methodologies. The main goals of these research endeavors are to (1) determine ideal mechanical properties, (2) devise methodologies to improve the efficacy of engineered corneal grafts and cell-based therapies, and (3) optimize transplantation of engineered tissue structures in the eye. Thus, recent innovations have sought to address these challenges through both in vitro and in vivo studies. This review covers recent work aimed at evaluating engineered materials, potential therapeutic cells, and the resulting cell-material interactions that lead to optimal corneal graft properties. Furthermore, we discuss promising strategies in corneal tissue engineering techniques and in vivo studies in animal models.

show abstract

“…Regenerative medicines for eye tissues focused on tissue engineering techniques have been developed and established as a new clinical field with enormous potential. In particular, the regeneration of ocular surface tissues such as the cornea or the limbus has greatly benefited from diverse tissue engineering developments (for a recent review, see [ 72 , 73 ]). Regarding human conjunctival tissue regeneration, some examples have been described in preclinical studies, but most of them have not yet been investigated in clinical studies.…”

Section: Potential Of Advanced Therapy Medicinal Products (Atmps) To Improve Conjunctival Treatmentmentioning

confidence: 99%

Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?

Diebold

García-Posadas

2021

Pharmaceutics

View full text Add to dashboard Cite

The conjunctiva is a complex ocular tissue that provides mechanical, sensory, and immune protection for the ocular surface. It is affected by many diseases through different pathological mechanisms. If a disease is not treated and conjunctival function is not fully restored, the whole ocular surface and, therefore, sight is at risk. Different therapeutic approaches have been proposed, but there are still unsolved conjunctival alterations that require more sophisticated therapeutic options. Advanced therapy medicinal products (ATMPs) comprise a wide range of products that includes cell therapy, tissue engineering, and gene therapy. To the best of our knowledge, there is no commercialized ATMP specifically for conjunctival treatment yet. However, the conjunctiva can be a potential target for ATMPs for different reasons. In this review, we provide an overview of the advances in experimental phases of potential ATMPs that primarily target the conjunctiva. Important advances have been achieved through the techniques of cell therapy and tissue engineering, whereas the use of gene therapy in the conjunctiva is still marginal. Undoubtedly, future research in this field will lead to achieving commercially available ATMPs for the conjunctiva, which may provide better treatments for patients.

show abstract

Stem cell-based therapeutic strategies for corneal epithelium regeneration

Cited by 24 publications

References 161 publications

Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency

Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency

Recent Advances in Natural Materials for Corneal Tissue Engineering

Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?

Contact Info

Product

Resources

About